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Background: The aetiology of multiple sclerosis (MS) remains unknown. This hampers molecular diagnosis and the
discovery of bio-molecular markers. Consequently, MS diagnostic procedures are complex and criteria for assessing
therapeutic efficacy are controversial, suggesting that a pathophysiological rather than an aetiological approach to
the disease would be more appropriate. In this regard, blood-proteomics represents a still-unexplored tool. We
investigated the potential of proteomics as applied to peripheral blood mononuclear cells (PBMCs) for
differentiating treatment-naive RR-MS patients from healthy controls and from IFN-treated RR-MS patients.
Methods: A comparative analysis of PBMC proteins isolated from 13 unselected IFN-treated RR-MS patients,
6 IFN-untreated RR-MS patients and 14 matched healthy controls was performed using two-dimensional gel
electrophoresis and MALDI-TOF mass spectrometry. We considered the volume of each spot, expressed as a
percentage of the total volume of all spots in the gel. Heuristic clustering was applied to a composite population
made up of a random sequence of gels from the different groups in comparison. For the differentially expressed
proteins, we applied the Student's t-test to identify only those down- or up-regulated at least 2.5-fold
[Ratio(R) ≥ 2.5] with respect to the homologous spots of the compared groups.
Results: Rho-GDI2, Rab2 and Cofilin1 were found to be associated with down-regulated and naïve group
phenotypes; Cortactin and Fibrinogen beta-Chain Precursor were found to be associated with down-regulated and
group-related IFN-treated RR-MS phenotypes. Thus, by means of similarity analysis, the proteomes were
homogeneously segregated into three distinct groups corresponding to naive, IFN-treated and healthy control
subjects. Interestingly, no separation was found between IFN-treated and healthy controls. Moreover, the molecular
phenotypes were consistent with disease pathogenesis.
Conclusions: We demonstrated for the first time, albeit only with preliminary data, the aprioristic possibility of
distinguishing naive and IFN-treated MS groups from controls, and naive from IFN-treated MS patients using a
blood sample-based methodology (i.e. proteomics) alone. The functional profile of the identified molecules
provides new pathophysiological insight into MS. Future development of these techniques could open up novel
applications in terms of molecular diagnosis and therapy monitoring in MS patients.
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Despite the extensive literature in the aetiological field,
infectious and genetic theories have failed to identify
the cause of the disease, and so multiple sclerosis (MS)
is an autoimmune pathology whose aetiology is still
unknown [1,2]. This is responsible for the lack of molecu-
lar diagnoses and therapy monitoring. On the other hand,
there is increasingly consistent pathogenetical evidence that
peripheral auto-reactive T-cells play a central role in pro-
voking inflammatory demyelination and axonal loss in the
brain parenchyma [3]. In addition, by acting on peripheral
T-cells, interferon-beta (IFN-β) is thought to reduce disease
activity, with an MRI-detectable effect in relapsing–remit-
ting multiple sclerosis (RR-MS) patients [4-6], confirming
the critical role of peripheral blood mononuclear cells
(PBMCs) in CNS damage [7].
Molecular mimicry and epitope spreading further
complicate aetiological investigation, suggesting that a
pathophysiological rather than an aetiological approach to
MS diagnosis may be more appropriate. Consequently,
the MS-patient is diagnosed by pathophysiological
evaluation of clinical or paraclinical dissemination in time
and space [8-10], and the only biological tests currently
considered to be of diagnostic relevance are oligoclonal
band assessment and the exclusion of MS-mimicking
conditions. Recently, proteomics has been successfully
used to study autoimmune diseases by contextualizing
the pathophysiological status of target cells (or tissues)
with reference to their protein expression profile, the
so-called molecular phenotype. This pathophysiology-
based point of view may allow MS to be studied regardless
of its aetiology. Dotzlaw H. and Schulz M. applied this
technique to the PBMCs of rheumatoid arthritis patients
and identified a differential fingerprint that separated
diseased from healthy control subjects [11,12]. In addition,
the resulting differentially expressed proteins helped
to elucidate the molecular mechanisms of the disease.
Blood-proteomics is also able to differentiate patients
with Alzheimer’s disease (AD) from healthy controls
by providing a panel of plasma-proteins that also predicts
progression to AD in preclinical patients affected by mild
cognitive decline [13].
More recently, we found a functional correlation in MS
patients between brain atrophy and the protein expression
profile of PBMCs, confirming their pathophysiological
involvement in disease evolution [14]. Despite the en-
couraging findings, to our knowledge, there has been no
attempt to electively elucidate the diagnostic potential
of PBMC-based proteomics in MS.
We assessed the potential of PBMC-based proteomic
analysis applied to a random, blind population made
up of IFN-untreated MS patients and healthy controls,
differentiating and separating them into homogeneous
groups. Secondarily we investigated the ability of thesame methodology to blindly differentiate IFN-treated
RR-MS patients from IFN-untreated (naïve) patients.
Methods
Study population
Three different classes of study population subjects were
enrolled in a case-controlled cross-sectional proteomic
study at the MS unit of “F. Ferrari” Hospital, Neurology
Division, Casarano (Le), Italy:
1) Thirteen (seven male, six female) consecutive
unselected IFN-treated RR-MS (RRt) patients taking 30
μg of interferon β-1a I.M. a week in accordance with
the international guidelines of Jacob et al. [15].
2) Six (three male, three female) consecutive
sex/age matched IFN-untreated RR-MS
(RRu, naïve) subjects.
All MS patients were previously diagnosed in
accordance with standard criteria [10] and gave
blood samples following a steroid- and
exacerbation-free period of at least three months.
Patients were selected for the study on the basis of
the following criteria: (i) they were in the RR phase
of the disease, classified in accordance with
standard disease course criteria [16]; (ii) they were
aged between 23 and 65; (iii) they had not
undergone any immune-modulation therapy
(naïve patients); (iv) they were prepared to express
written informed consent. Patients who had been
treated with immunosuppressive drugs or were
affected by other comorbidity conditions were
excluded from this study. Only non-interfering
symptomatic therapy was tolerated.
3) Fourteen (seven male, seven female) age/sex
matched healthy controls (HC).
All subjects were enrolled and underwent blood sampling
after expressing informed written consent. Approval of
this study was provided by the local hospital and by the
ethics committee of the Local Health Authority of Lecce
(ASL/LE).
PBMC isolation and lysis
Heparinized blood (15 ml) was collected by venipuncture
and immediately processed. First, blood was centrifuged at
150 × g for 5 min and the platelet-enriched supernatant
was removed. The pellet was then diluted with PBS
(Phosphate Buffered Saline) solution and layered on a Ficoll
density gradient (GE Healthcare). Subsequently, PBMCs
were isolated by centrifugation (400 × g for 40 min) and
processed within 1h. After isolation, the lympho-monocytes
were washed twice in PBS and lysed in 0.5 ml of sam-
ple buffer (CHAPS) and protease inhibitor cocktail.
To minimize nucleic acid interference with protein
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(low amplitude). Finally, protein concentration was deter-
mined by Bradford’s method (Bio-Rad Protein assay).
Two-dimensional gel electrophoresis
First dimension run
Sample loading: 80 μg of proteins were mixed with
rehydration solution (7 M Urea, 2 M thiourea, 4%
CHAPS, 50 mM DTT and 0.8% IPG Buffer) to obtain
a final volume of 250 μl. The samples were incubated
for 30 min at 4°C and applied to 13 cm IPG pH 4–7
gel strips (Amersham Biosciences).
Isoelectric focusing (IEF): IEF was performed with an
IPGphor system (GE Healthcare) in 7 steps by gradually
increasing the voltage after rehydration for 4 h: 30 V for
12 h, from 30 V to 500 V in 30 min, 500 V for 1 h, from
500 V to 1000 V in 30 min, 1000 V for 1 h, gradient
from 1000 V to 8000 V in 30 min, 8000 V for 2 h, making a
total of 20,617 Vh.
Equilibration: after IEF, the strips were equilibrated in 6
M Urea, 50 Mm Tris–HCl (pH 8.8), 30% glycerol, 2% SDS
and 10 mg/ml DTT for 18 min, followed by 25 mg/ml
iodoacetamide for 10 min.
Second dimension run
The second dimension was performed on a 9-16% gradient
SDS-polyacrylamide gel (16 × 18 cm, 1.5 mm thick)
and run at a constant current of 28 mA/gel at 8°C until
the BPB reached the anodic end of the gel. Wide range
protein standard (Sigma-Aldrich) was loaded together
with the sample.
Development and staining: proteins were visualized by
ammoniacal silver staining, adding thiosulfate after the
gel polymerization step [17]. Each sample was run in
duplicate, making a total of sixty-six gels subjected to
2-D electrophoresis.
Image and statistical analysis
Gel images were acquired using an Image Scanner
(GE Healthcare), with a scanning resolution of 300Table 1 Clinical and demographic features of treated MS (RRt
RRt (n = 16) HC
range mean SD range
DISEASE DURATION 2.0-14.0 7.43 4.5
AGE AT STUDY 23.0-65.0 42.6 11.1 22.2-64.3
EDSS 0.0-5.0 2.0 1.7
SEX RATIO (♀/♂) 56%/44% 58
p1,2,3: p value of comparison between HC/RRt, RRu/RRt, RRu/HC groups respectively.dpi. Spot detection, matching and data analysis were
performed with Image MasterTM 2D Platinum software,
version 5.0 (GE Healthcare). The gels were divided into
three classes (healthy controls, IFN-untreated RR-MS
patients and IFN-treated RR-MS patients) and a refer-
ence gel with the highest number of spots was created
for each class. The software was then used to detect
and match spots between gels by the matching method
included in the software package. Spot detection and
spot matches were corrected manually where necessary.
The analysis was carried out by comparing the volume of
each spot expressed as a percentage of the total volume of
all spots in the gel.
Heuristic clustering was used on a random population
composed of a blind sequence of gels from the classes
in comparison. This analysis assigned each gel to a
homogenous subclass depending on the similarity between
each spot and its homologue in all the other gels in
comparison. The Student’s t-test was applied to the
differentially expressed proteins in order to identify
only those down- or up-regulated at least 2.5-fold
[Ratio(R) ≥ 2.5] with respect to homologous spots of the
compared groups. In addition, Leven’s test was applied to
every differentially expressed spot to assess the similarity
of variance between the compared groups.
Cluster analysis was applied first to a composite
population made up of naïve patients and healthy controls,
and then to a composite population made up of IFN-
treated and untreated RR-MS patients. In both cases
we used a random blind sequence of gels.
Protein identification
For preparative mass spectrometry analysis, gels were
stained with MS-compatible silver staining or with Blue
Silver colloidal Coomassie [18,19].
Silver stained spots were excised from preparative gels
and destained with hydrogen peroxide and ammonium
bicarbonate as reported by Sumner et al. [20]. Coomassie
stained spots were processed by incubating with 50 μl of
50 mM NH4HCO3 in 40% ethanol until full decolouration.
The spots were then incubated with 50 μl of acetonitrile
for 10 min. The dried gel pieces were rehydrated in 16 μl
(20 μg/ml) of trypsin solution (Sigma) and digested
overnight at 37°C.), untreated MS (RRu) and healthy control (HC) subjects
(n = 12) RRu (n = 6) p value
mean SD range mean SD
2.9-13.9 7.83 3.9 p = 0.15
41.8 10.6 20.9-66.0 42.9 12.2 p1,2,3≥ 0.22
%/42% 57%/43
Figure 1 Reference map of PBMCs. Spots showing differential
expression are indicated.
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reverse phase extraction using ZipTip C18 microcolumn
(Millipore, CA, USA). Peptides were directly eluted
with 2 μl of α-cyano-4-hydroxycinnamic acid in 33%
acetonitrile, TFA 0.1%, on a ground steel MTP 384 target
(Bruker Daltonics).
MALDI-TOF analyses were performed on a Reflex IV
mass spectrometer (Bruker Daltonics) in reflectron positive
ion mode after internal and external calibration of the
spectrum. The MALDI mass spectrum was externally
calibrated with the peptide standard calibration II mixture
(Bruker Daltonics) and then internally calibrated with
trypsin autodigestion products (842.51 m/z, 1045.56 m/z
and 2239.14 m/z). Analyses were carried out in the mass
range from 700 to 4000 m/z and about 300 laser shots were
taken for each spectrum.
Database searches were conducted with the MS-Fit or
Mascot programs against Swiss-Prot and NCBI databases
with the following parameters: human species, mass
tolerance of 50 ppm, one missed cleavage site for tryptic
peptides, allowing the modification of carbamidomethylation
(C) and variable oxidation (M).Table 2 Identified proteins and corresponding Mascot score
Entry name Peptide matches Swiss-Prot AC number Des
COF1 8 P23528 Cofilin 1 (non
SRC8 22 Q14247 Src substrate c
FIBB 31 P02675 Fibrinogen be
GDIR 10 P52565 Rho GDP-disso
GDIA 25 P31150 Rab GDP dissociResults
Demographic characteristics were comparable in the
diseased and control groups (Table 1). The mean duration
of IFN-based therapy at the start of the study was 7 years.
Figure 1 shows a reference map of PBMCs where all
the spots showing differential expression are indicated.
A list of them with their Mascot identification data is
shown in Table 2.
The heuristic clustering dendrogram indicated complete
separation between the gels of healthy controls and those
of diseased IFN-untreated patients (Figure 2); complete
separation was also obtained between the gels of IFN-
untreated and IFN-treated patients (Figure 3). These results
were obtained by applying cluster analysis to one popula-
tion composed of a random blind sequence of all the gels
of HC and RRu subjects and another composed of all the
gels from the RRu and RRt patients.
In the first case, the differentially expressed proteins
were: Rho-GDI2, Rab GDIβ (Rab2) and Cofilin 1. In the
second case, the differentially expressed proteins were:
Cortactin and the Fibrinogen β Chain Precursor. Specific-
ally, Rho GDI2, Rab2 and Cofilin were found to be down-
expressed in IFN-untreated patients in comparison to
healthy controls, while Cortactin and Fibrinogen β chain
precursor were found to be up-regulated in the untreated
group compared to the treated group. Moreover, equality of
variance was found in all the compared groups, except for
Cofilin between the IFN-treated and untreated groups
(R and Leven’s tests in Table 3). Figure 4 shows the
shape of the most representative spots.
Lastly, clustering analysis applied to a population made
up of a random blind sequence of all the gels from the
RRt patients and HC subjects showed no homogeneous
class separation.
All the differentially expressed spots sequenced by
MALDI-TOF analysis exhibited R ≥ 2.5 (p ≤ 0.001).
Discussion
This study assessed the aprioristic potential of proteomics
for discriminating between RR-MS subjects and healthy
controls and between IFN-treated RR-MS patients and
untreated patients. Blind heuristic clustering applied to
a random population of PBMC gels from IFN-treated
and untreated MS patients was able to separate treated
from naïve subjects and the latter from healthy controls.cription pI Mw pI Mw Coverage Score Mascot
-muscle isoform) 8.3 18371 5.91 19 57% 107
ortactin (Amplaxin) 5.2 61637 5.08 85 35% 207
ta chain precursor 8.5 55929 6.03 42 54% 227
ciation inhibitor 1 5.0 23076 4.96 26 39% 88
ation inhibitor alpha 5.0 50583 4.99 59 52% 304
Figure 2 Dendrogram indicating complete separation between gels from healthy controls and IFN-untreated patients.
Figure 3 Dendrogram indicating complete separation between gels from IFN-untreated and IFN-treated patients.
De Masi et al. BMC Neurology 2013, 13:45 Page 5 of 8
http://www.biomedcentral.com/1471-2377/13/45
Table 3 Differentially expressed proteins with % volume and related statistical parameters of treated MS (RRt),
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were found to be down-regulated in naïve patients, and
Cortactin and Fibrinogen β Chain Precursor were
found to be down-regulated in the IFN-treated group.
Each group of gels belonging to a dendrogram branch
was separated from the other branches by the presence
of differentially expressed spots exhibiting two key
features: the non-overlapping mean % volume values and
the large difference between the mean values (at least two
and a half times the mean absolute value) of the % volume
of each sub-group.
Although these findings represent preliminary data,
they demonstrate for the first time the concrete role of
proteomics in the molecular diagnosis of MS. Moreover,
proteomics is able to distinguish the PBMC profile of an
IFN-treated patient from that of a naïve one. This latter
finding may seem to be of low importance, but it could
contribute to the molecular characterization of patients
who do not respond to interferon therapy.Figure 4 Shape of most representative spots.In addition, our data confirmed, at a molecular level,
the disregulation and consequent diversion of the immune
system to the “self” in MS patients. We also found quantita-
tive rather than qualitative differences between the PBMC
profile of naïve patients and that of healthy controls. This is
in line with our previous work, which did not find a differ-
ential pattern in MS. The application of cluster analysis in
the present study is seen to have a diagnostic value based
on a pathophysiological methodology, and the differentially
expressed proteins identified here exhibit a coherent func-
tional profile in the pathophysiological context of MS.
Rho-GDI2 and Rab GDIβ (Rab2) are key GTPase
inhibitors: they regulate a group of high-level proteins
in cell biology and are involved in various fundamental
cellular events including secretion, proliferation, intra-
cellular signalling, cytokinesis, vesicular trafficking and
lymphocyte extravasation through blood-CNS barriers.
Three general classes of GTPase signalling regulators
have been identified: guanine nucleotide exchange factors
(GEFs), GTPase-activating proteins (GAPs) and guanine
nucleotide dissociation inhibitors (GDIs).
Rho-GDI proteins form a large complex, with the
Rho protein helping to prevent diffusion within the
membrane and the cytosol [21]. Rho GTPases at the
plasma membrane are in turn known to be associated
with TCR cascades following antigen recognition in the
presence of MHC molecules. This association is developed
by the ZAP-70 protein. A substrate for its activity is the
adapter molecule LAT (linker for activation of T cells),
linked to the Rho/Rac domain in a multi-protein signalling
complex that includes PLCγ, Grb2 and Ras. They are the
main effectors for intracellular actin dynamics and gene
expression. Interestingly, there is much evidence to indicate
that Rho GTPase is a critical signalling intermediate in
vascular inflammation and inflammatory injury.
Rab2 proteins are monomeric GTPases specializing in
vesicular trafficking, as their sub-cellular localization in
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with the SNARE system, thereby coupling membrane
cohesion to their fusion.
It thus seems clear that GDI represents a pivotal
regulator of the major cellular functions that support
the same abnormal mechanisms postulated in MS
pathogenesis. The GDI down-expression in the PBMCs
of naïve MS patients is evidence for the basal inflammatory
activity of leukocytes, as expected in a chronic inflam-
matory disease. Consistently, GDI down-expression was
not seen in the IFN-treated MS group. Indeed, the
anti-inflammatory effects of β-interferon, with notable
reduction in cell trafficking, secretion, proliferation
and leukocyte extravasation, are well known. Likewise,
Cofilin, a ubiquitous eukaryotic actin-binding protein
with actin-severing activity, was seen to be down-expressed
in the IFN-treated group.
The down-expression of Cortactin and the Fibrinogen
β Chain Precursor in the treated MS-group again suggests
a pharmacological effect. Indeed, the former, which is
over-expressed in human carcinoma cells, is implicated
in the modulation of cellular adhesion; the latter is an
extracellular protein that stimulates leukocyte functional
activity and adhesion during inflammation [22-24].
Thus we argue that naïve RR-MS is characterized
by chronic, basal activation of the fundamental pro-
inflammatory mechanisms correlated with Rho and
Rab2 GDI de-inhibition. This condition does not seem
to characterise IFN-treated patients, as also suggested
by the decrease in Cortactin and Fibrinogen beta chain
precursor in the RRt group.
In the literature, the main proteomic results have been
obtained in neoplasmic, genetic and infectious diseases that
are characterized by aberrant molecular phenotypes such
as disease-specific differentially expressed proteins. In our
study, rather than aberrant phenotypes we found aberrant
expression of normal proteins. Our differentially expressed
proteins thus do not appear to indicate pathological
specificity, but reflect the functional condition of PBMCs.
One weakness of our study is the limited population,
but two other elements need to be considered: with the sole
exception of Cofilin, the low and homogenous magnitude
of inter-group and intra-group data dispersion confirms
the accuracy of the method; the difference in protein
expression over the third standard deviation makes the
study fairly robust.
Conclusions
Although our statements refer to a population already
screened for other MS-like conditions, we can conclude
that PBMC proteomics coupled with heuristic clustering
is able to distinguish treatment-naïve MS patients from
healthy control subjects and IFN-treated patients from
untreated patients.Lastly, Rho- and Rab2-GDI inhibitors, Cofilin, Cortactin
and the Fibrinogen beta chain precursor can improve our
knowledge of the pharmacodynamics of β-interferon and
the pathophysiology of MS. Although further confirmation
by means of routine-based techniques is warranted, they
should be considered as potentially clinically relevant sig-
nalling factors in the laboratory criteria of IFN-responding
RR-MS patients and in the early diagnosis of the disease.
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